Clinical Trials Browser

Phase 1/2 × Has results × eribulin × Clear all

NCT04345913 2026-03-19

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Phase 1/2 Active not recruiting

24 enrolled 24 charts

Triple Negative Breast Neoplasms

NCT03526679 2025-12-05

LEADER

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT05041101 2025-06-13

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Inflammatory Breast Neoplasms

NCT01126736 2023-06-22

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

Phase 1/2 Completed

98 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03245450 2022-06-28

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

Phase 1/2 Completed

40 enrolled 30 charts

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT02513472 2022-05-05

ENHANCE-1

Phase 1/2 Completed

258 enrolled 18 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01126749 2022-02-28

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Phase 1/2 Terminated

92 enrolled 15 charts

Urinary Bladder Neoplasms

NCT01554371 2021-02-03

Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

Phase 1/2 Completed

44 enrolled 14 charts

Breast Neoplasms, Carcinoma

NCT01323530 2021-01-11

A Confirmation Study of Eribulin in Combination With Capecitabine

Phase 1/2 Completed

76 enrolled 24 charts

Breast Neoplasms

NCT01596751 2020-07-17

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Phase 1/2 Completed

67 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02753595 2020-07-13

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Phase 1/2 Terminated

25 enrolled 9 charts

Breast Neoplasms

NCT01388647 2015-08-28

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Phase 1/2 Terminated

12 enrolled 12 charts

HER-2 Positive Breast Cancer